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Metabolic reprogramming during neuronal
differentiation
M Agostini1,2,6, F Romeo1,3,6,7, S Inoue4, MV Niklison-Chirou1,8, AJ Elia4, D Dinsdale1, N Morone1, RA Knight1, TW Mak4 and
G Melino*,1,2,5
Newly generated neurons pass through a series of well-defined developmental stages, which allow them to integrate into existing
neuronal circuits. After exit from the cell cycle, postmitotic neurons undergo neuronal migration, axonal elongation, axon pruning,
dendrite morphogenesis and synaptic maturation and plasticity. Lack of a global metabolic analysis during early cortical neuronal
development led us to explore the role of cellular metabolism and mitochondrial biology during ex vivo differentiation of primary
cortical neurons. Unexpectedly, we observed a huge increase in mitochondrial biogenesis. Changes in mitochondrial mass,
morphology and function were correlated with the upregulation of the master regulators of mitochondrial biogenesis, TFAM and
PGC-1α. Concomitant with mitochondrial biogenesis, we observed an increase in glucose metabolism during neuronal
differentiation, which was linked to an increase in glucose uptake and enhanced GLUT3 mRNA expression and platelet isoform of
phosphofructokinase 1 (PFKp) protein expression. In addition, glutamate–glutamine metabolism was also increased during the
differentiation of cortical neurons. We identified PI3K–Akt–mTOR signalling as a critical regulator role of energy metabolism in
neurons. Selective pharmacological inhibition of these metabolic pathways indicate existence of metabolic checkpoint that need
to be satisfied in order to allow neuronal differentiation.
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Although the brain represents only about 2% of body weight,
it consumes 20% of the body’s energy. This high-energy
demand is mainly required for restoration of the membrane
gradient, after neuronal depolarization, as well as for
neurotransmitter recycling, intracellular signalling and dendri-
tic and axonal transport.1 Neurons use mainly glucose as a
source of energy, which is almost entirely oxidized through
sequential glycolysis and the tricarboxylic cycle (TCA)
associated with oxidative phosphorylation. However, under
some circumstances, such as hypoglycaemia, neurons can
use glutamate and glutamine for energy production.2 The
deamidation of glutamine produces glutamate, which is then
oxidized via the TCA cycle, being an efficient energy
generator.3,4 To date, however, relatively few reports have
addressed the metabolic changes occurring during neuronal
differentiation, although mitochondrial morphology and traf-
ficking are known to vary as a function of the differentiation
stage.5 In line with this, inhibition of mitochondrial protein
synthesis by chloramphenicol (CAF) arrests the differentiation
of neuroblastoma cell lines.6
Once neuronal progenitors exit from the cell cycle, the
immature postmitotic neurons engage in a series of develop-
mental events.7,8 Although this process is complex and highly
regulated, it can be summarized in the following steps:
(i) axo-dendritic polarization; (ii) migration to reach their final
destination; (iii) growth of the axon and dendritic arborization;
and (iv) synapse formation. Several observations indicate that
both extrinsic signals and intrinsic pathways are required for
the regulation of this developmental process.7,9 However, little
is known about the contribution of cellular metabolism on
cortical neuron differentiation. In order to investigate the
metabolic changes during this process, we employed an
in vitro model of terminal differentiation of cortical neurons,
which has been extensively used as amodel to study neuronal
cell biology.10
Here we have used this model in order to investigate the
role of cell metabolism, in particular energy metabolism,
during neuronal differentiation. Our findings reveal a key
role in the regulation of neuronal differentiation for three
metabolic pathways: glycolysis, mitochondrial biogenesis,
and the glutamine–glutamate pathway. In addition, we show
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that PI3K–Akt–mTOR (mammalian target of rapamycin)
signalling regulates mitochondrial bioenergetics and function.
This is in keeping with the relevant role exerted by
the PI3K–Akt–mTOR pathway in regulating dendritic morpho-
genesis, and accordingly, its genetic or pharmacological
inhibition results in reduced dendrite size and dendritic
complexity.11,12
Results
Neuronal differentiation is associated with mitochondrial
biogenesis. Mitochondrial biogenesis has been linked to
several physiological and pathological processes in the
brain.13–15 In order to investigate whether mitochondrial
biogenesis is associated with cortical neuron differentiation,
we first evaluated, by real-time PCR, the relative mitochon-
drial DNA (mtDNA) levels at different stages of differentiation.
The results in Figure 1a show that levels of mtDNA
progressively and significantly increased during differentia-
tion. To confirm that this increase in mtDNA truly reflected an
increase in mitochondrial mass, we also assayed the protein
levels of the different complexes of the electron transport
chain (ETC).16 The western blotting in Figure 1b shows
that several subunits of the ETC, namely, ATP5A (mitochon-
drial membrane ATP synthase F(1)F(0) ATP synthase or
Complex V), UQCRC2 (ubiquinol-cytochrome c reductase
core protein II), MTCO1 (mitochondrially encoded cyto-
chrome c oxidase I), SDHB (succinate dehydrogenase
complex, subunit B, iron sulphur) and NDUF0B9, increased
during neuronal differentiation. Interestingly, the increase in
mitochondrial biogenesis was also observed in vivo during
postnatal brain development (Figures 2a and b). We also
observed a change in mitochondrial morphology during
cortical neuron differentiation. Indeed, as shown in Figure 1c,
at day in vitro 1 (DIV1) most of the mitochondria have a
rounded shape and a condensed matrix, while at DIV7 there is
a significant increase of mitochondria with an elongated shape
and a more typical structure.17 However, these changes were
not observed in vivo during postnatal brain development at the
time investigated (Supplementary Figure S1a).
Several transcription factors, such as peroxisomal prolifer-
ating activating receptor γ coactivator-1α (PGC-1α), mitochon-
drial transcription factor A (TFAM) and nuclear respiratory
factor (NRF-1/2), have a key role in the regulation of
mitochondrial biogenesis.18 Therefore, we monitored the
protein levels of these transcription factors along cortical
neuron differentiation, and as shown in Figure 1d, TFAM and
PGC-1α were indeed upregulated during the differentiation,
although no differences in the expression of NRF-1 were
observed (Supplementary Figure S2a). As myocyte enhancer
factor-2 (MEF-2) is also involved in the regulation of
mitochondrial biogenesis through its interaction with
PGC-1α19 and has also been implicated in the regulation of
neuronal differentiation,20 we investigated changes in the
expression of MEF-2 in our system. Western blotting analysis
shows that during neuronal differentiation the expression of
MEF-2 is indeed increased (Figure 1d). However, the
expression of structural protein such as cyclophilin D does
not change during neuronal differentiation as shown in
Supplementary Figure S2b.
To determine the importance of PGC-1α and NRF-1, we
have also tested their transcriptional activity by assessing the
mRNA levels of their target genes.21,22 As shown in
Figures 1e and f, cortical neuron differentiation was also
associated with an increase in the mRNA expression of
glutathione peroxidase 1 (Gpx1) and transcription factor B2,
mitochondrial (Tfb2m).
Previously, it has been show that inhibition of mitochondrial
protein synthesis prevents cell differentiation.6 To investigate
whether this was also the case for cortical neurons, DIV1
cortical neurons were treated with CAF at a concentration that
does not induce cell death (Supplementary Figure S3c).
Supplementary Figures S2c and d show that inhibition of
mitochondrial protein synthesis led to a significant (about
58%) reduction of neuronal differentiation, with the neurons
having an arrested morphology characteristic of stage 3–4
according to Dotti et al.10 classification.
Together, these results indicate that mitochondrial biogen-
esis occurs during cortical neuron differentiation and most
likely to be regulated by TFAM, PGC-1α and MEF-2.
Mitochondrial function and cortical neuron differentia-
tion. The observed mitochondrial morphological changes
associated with neuronal differentiation led us to investigate
whether mitochondrial bioenergetics was also affected during
the differentiation of cortical neurons. To do this, we used the
extracellular Flux Analyser that allows the measurement of
the oxygen consumption rate (OCR, mitochondrial respira-
tion) and the extracellular acidification rate (ECAR, glycoly-
sis) in real time. We found that the basal respiration of fully
differentiated cortical neurons (DIV7) was higher than that of
immature cortical neurons (DIV1) as shown in Figure 3a
(before oligomycin was added). Then we assessed the
function of individual ETC complexes in DIV7 and DIV1
cortical neurons by sequentially adding pharmacological
inhibitors of the respiratory chain. When oligomycin was
added, a decrease in OCR occurred in both undifferentiated
and differentiated cortical neurons to approximately the same
extent (Figure 3b–i). This suggests that the mitochondrial
oxygen consumption used for ATP synthesis does not
change during cortical neuron differentiation. Moreover, the
remaining OCR can be ascribed to proton leakage, which, as
shown in Figure 3b–ii, is not affected by the differentiation.
Next we determined the maximal OCR that the cells can
sustain by adding carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP). This treatment resulted in a
stimulation of the OCR, which was significantly higher in
the differentiated cells as shown in Figure 3b–iii. FCCP did
not increase the OCR in the undifferentiated cells above
the basal rate, and unlike the differentiated neurons, the
undifferentiated cells have no spare respiratory capacity
(Figure 3b–iv). In differentiated cells, the OCR is significantly
increased by the uncoupler by about 60%. Finally, we added
Rotenone, which dramatically suppressed the OCR. No
differences were observed in non-mitochondrial respiration
(Figure 3b–v). Moreover, ECAR, which provides a quantifica-
tion of glycolytic flux, was only present at DIV7 cortical
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neurons, confirming the increase of glycolysis during
differentiation (Figures 3c and 4a).
Overall, these findings show that cortical neuronal differ-
entiation is associated with a functional reprogramming of
mitochondria.
Global metabolic profiling during in vitro neuronal
differentiation. Then we asked whether other metabolic
changes were associated with the mitochondrial biogenesis.
To do so, cortical neurons were isolated from E16 embryos
and allowed to terminally differentiate in vitro as previously
0 
2 0 
4 0 
6 0 
8 0 
10 0 
%
 o
f M
ito
ch
on
dr
ia
D I V 7 
D I V 1 
DIV1 DIV7 
Round         Elongate 
p=0.022 
p=0.026 
R e l a t i ve m t DNA l eve l s 
D IV 1 D IV 3 D IV 5 D IV 7 
0 
2 
4 
6 
p=0.014 
p=0.0005 
TFAM
GAPDH
GAPDH
PGC-1α
DIV    1      3      5       7
GAPDH
MEF-2
DIV  1      3     5     7 
GAPDH 
CV-ATP5A 
CIII-UQCRC2 
CIV-MTCO1 
CII-SDHB 
CI-NDUF0B8 
TFAM/GAPDH       1     1.7      2     1.4
PGC1α/GAPDH    1      1.1    1.9    2.1
    1      3.9      6     3.3   MEF2/GAPDH
50 - 
37 - 
25 - 
37 - 
20 - 
- 100
- 37
- 37
- 37
- 25 - 75
DIV   1      3      5       7
0
0.5 
1
1.5 
2 
DIV1 DIV3 DIV7 
Gpx1 
Sod1 
0 
0.5
1 
1.5
2
DIV1 DIV3 DIV7
Tfb2m 
Cox2
PGC-1α target genes NRF-1 target genes 
m
R
A
N
 re
la
tiv
e 
ex
pr
es
si
on
Figure 1 In vitro terminal differentiation of cortical neurons is associated with mitochondrial biogenesis. (a) Relative quantification of mtDNA copy number during
differentiation of cortical neurons. Real-time PCR was performed with primers against a single-copy nuclear gene succinate dehydrogenase complex, subunit A and the
mitochondrially encoded NADH dehydrogenase 5 gene. (b) Expression of the different complexes of ETC increases along the differentiation. Western blotting was performed with
MitoProfile Total OXPHOS. (c) Transmission electron microscopy analysis of DIV1 and DIV7 neurons. The mitochondria at DIV1 are small and rounded, with a dense matrix. At
DIV7, the mitochondria have a much less dense matrix and the percentage of mitochondria with elongated shape increase, as shown in the graph (right panel). For comparison,
we restricted imaging to the perinuclear/Golgi region. (d) Western blotting analysis of the transcription factors TFAM, PGC-1α, MEF-2 and NRF-1 during in vitro terminal
differentiation of cortical neurons. Numbers indicate densitometric analysis of a representative experiment. (e and f) RNA levels of the indicated PGC-1α and NRF-1 target genes
during in vitro terminal differentiation of cortical neurons, respectively. RNA levels were assessed by real-time PCR
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described.23 Cells were harvested for global metabolic
profiling at DIV2, DIV5 and DIV7 to identify changes
associated with differentiation. A large number of biochemical
changes, associated with glycolysis, lipid metabolism, synth-
esis of neurotransmitters and cellular stress, were observed
during differentiation of cortical neurons (Supplementary
Table S1).
First, an increase in glucose metabolism was observed with
an accumulation of glycolytic metabolites, such as glucose-6-
phosphate, glycerate, 2-phosphoglycerate, phosphoenolpyr-
uvate and lactate between DIV2 and DIV7 (Figure 4a). These
changes in classical glycolysis were accompanied by an
increase in the pentose phosphate pathway (PPP) intermedi-
ates, 6-phosphogluconate and sedoheptulose-7-phosphate.
Thus these data suggest that glucose oxidation increases
during cortical neuron differentiation to produce biosynthetic
precursors and NADPH-reducing equivalents for the synth-
esis of amino acids and lipids (Supplementary Table S1). We
also observed an increase in long-chain fatty acids with an
increase in lysolipids, whereas medium-chain fatty acids
decreased, over time (Supplementary Table S1). Together
with the observed increase in citrate and cholesterol synthesis
and the lack of acyl-carnitine conjugates, these data suggest
increased fatty acid synthesis and membrane remodelling
(Supplementary Table S1). In addition, and consistent with
the fully differentiated neuronal phenotype at DIV7, the
concentration of several neurotransmitters (glycine, serine,
glutamate and GABA) significantly increased over time in
cultured neurons (Supplementary Table S1). The precursors
of dopamine and serotonin, tyrosine and tryptophan, respec-
tively, also increased significantly.
Glucose metabolism increases during differentiation of
cortical neurons. Glucose is the main source of energy in
the brain.24 The global metabolic profile indicates that
glycolytic activity is increased during in vitro differentiation
of cortical neurons. The rate of glycolysis is tightly regulated,
in particular by three key enzymes: hexokinase, phospho-
fructokinase-1, and pyruvate kinase (Figure 4b). Therefore,
we next asked whether the expression of these enzymes was
increased during cortical neuron differentiation in parallel with
the increased glycolytic flux. Total RNA was extracted at
different days and the expression of these enzymes was
monitored by real-time PCR. As shown in Supplementary
Figure S3a, PFKp expression was significant increased over
time although no significant changes in HK-1 and PKM
expression were observed. Increase of PFKp expression was
also confirmed at protein levels (Figure 4c). Moreover, we
also found increased expression at the mRNA level of the
glucose transporter 3 (GLUT3; neuron specific, Figure 4d).
The increased GLUT3 expression would be expected to
increase glucose uptake. To test this, we incubated cortical
neurons with the fluorescent deoxyglucose analogue and the
fluorescence intensity was evaluated by flow cytometry. As
shown in Figure 4e, the mean fluorescence intensity is
significantly increased, indicating an increase of glucose
uptake early in differentiation.
To test whether glucose metabolism is required for neuronal
differentiation, DIV1 cortical neurons were treated with
2-deoxy-D-glucose (2-DG) a competitive inhibitor of glycolysis.
No apoptosis was detected at the concentration used
(Supplementary Figure S3c). As shown in Figures 4f and g,
cortical neuron differentiation was inhibited by roughly 75% in
the presence of 2-DG, and neuronswere arrested in stage 2 of
the differentiation. Moreover, inhibition of glucose metabolism
led to a significant reduction (about 30%) in the endogenous
levels of ATP (Figure 4h).
These results indicate that the upregulation of glucose
metabolism during cortical neuron differentiation is linked to an
increase in GLUT3 and PFKp expression with corresponding
increases in glucose uptake and glycolytic flux and this
enhanced glucose metabolism is required for the full
differentiation of cortical neurons.
Glutamine–glutamate metabolism and differentiation of
cortical neurons. Glutamate is the main excitatory neuro-
transmitter in the brain.2 However, it has many other
functions, including its oxidation for energy production
(through its oxidative deamination to α-ketoglutarate, forma-
tion of GABA and glutathione (GSH) synthesis (Figure 5a).
The global metabolic profile analysis shows that glutamate
and GABA are significantly upregulated during differentiation
of cortical neurons while no differences are observed in
glutamine levels (Figure 5b and Supplementary Table S1).
This prompted us to investigate the expression of several
enzymes involved in the pathway depicted in Figure 5a.
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Figure 2 Mitochondrial biogenesis during postnatal development of murine
cerebral cortex. (a) Relative quantification of mtDNA copy number at the indicated
postnatal day. Real-time PCR was performed with primers against a single-copy
nuclear gene succinate dehydrogenase complex, subunit A and the mitochondrially
encoded NADH dehydrogenase 5 gene. (b) Expression of the different complexes of
ETC increases along the postnatal development of cerebral cortex. Western blotting
was performed with MitoProfile Total OXPHOS. A representative experiment is
shown. P, postnatal day. *Aspecific
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In neurons, glutamate is mainly produced by the deamidation
of glutamine by glutaminase 1 (GLS1) and 2 (GLS2).25 We
therefore monitored the expression of these enzymes during
cortical neuronal differentiation. The mRNA levels of GLS1
and GLS2 are significantly increased from DIV3 to DIV7 as
assessed by real-time PCR (Figure 5c). However, upregula-
tion of GLS2 mRNA was not associated with an increase at
protein levels (Supplementary Figure S3b). Endogenous
glutamate can either feed the TCA cycle or be converted
into GABA. Glutamate enters the TCA cycle after conversion
into α-KG by glutamate dehydrogenase 1 (GLUD1). As
shown in Figure 5d, expression of GLUD1 mRNA is also
increased during differentiation of cortical neurons. Increased
GLUD1 expression (and hence increased α-KG), results in an
increase in some downstream TCA metabolites, such as
citrate and malate Supplementary Table S1). Finally, gluta-
mate can also be converted into GABA, by the action of
glutamic acid decarboxylase (GAD). Western blotting
analysis (Figure 5e) shows that expression of GAD67, one
of the two GAD isoforms expressed in brain, increases during
neuronal differentiation.
To assess the biological importance of glutamine metabo-
lism in neuronal differentiation, we treated DIV1 cortical
neurons with 6-diazo-5-oxo-L-norleucine (DON),26 a selective
inhibitor of GLS. DON treatment resulted in a significant
reduction of neuronal differentiation (Figures 5f and g), with
neurons showing stages 3–4 morphology. In addition,
intracellular levels of ATP were reduced (Figure 5h).
Overall, these results indicate that glutamine–glutamate
metabolism is increased during the differentiation of cortical
neurons and its inhibition reduces cortical neuron differentia-
tion as well as endogenous levels of ATP.
The PI3K–Akt–mTOR pathway regulates mitochondrial
bioenergetics. Several reports have shown that mTOR
signalling controls neuronal development and plasticity.27
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Moreover, the mTOR pathway has a key role in the regulation
of cellular metabolism in non-neuronal tissues.28 Therefore,
we asked whether mTOR also has a role in the metabolic
changes observed during neuronal differentiation. To do this,
DIV1 cortical neurons were treated with rapamycin, and as
expected, rapamycin treatment resulted in a reduction of
phosphorylated S6K (Figure 6a) together with a reduction in
neuronal differentiation (Figure 6b). More importantly, mito-
chondrial biogenesis (Figure 6d) as well as the mitochondrial
maximal respiration rate and the spare respiratory capacity
(Figures 6e and f) were also significantly reduced after
rapamycin treatment. The PI3K/Akt–mTOR pathway coop-
erates with the MAPK/ERK signalling to regulate dendrite
complexity.11 Therefore, to better characterize the molecular
pathways involved and the relative contribution of each of
them to the metabolic changes observed during neuronal
differentiation, DIV1 cortical neurons were treated with the
selective pharmacological inhibitors at concentrations that do
not induce cell death (Supplementary Figure S3c). Inhibition
of PI3K by LY294002 led to a reduction of pS6 phosphoryla-
tion levels as well as a reduction in the endogenous levels of
MEF2 and TFAM as shown in Figure 6c that was associated
with a significant reduction of mitochondrial mass as shown
by the relative levels of mtDNA (Figure 6d). The same effects
were observed when cortical neurons were treated with
PD98059, a MAPK pathway inhibitor. In addition, at the
functional level, as shown in Figure 6e, LY294002 signifi-
cantly reduced the maximal respiration rate and spare
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Figure 5 Glutamine–glutamate cycle increase during in vitro terminal differentiation of cortical neurons. (a) A schematic representation of Glutamine–glutamate pathway in cortical
neurons. In red, the genes assayed. (b) Glutamate and GABA levels increase during cortical neuron differentiation. Levels of the indicated metabolites were evaluated as described in
Materials and Methods section. Welch’s two-sample t-tests were used to identify biochemicals that differed significantly between experimental groups (n= 5 for each time point). (c and
d) mRNA levels of glutaminase type 1 (GLS1), type 2 (GLS2) and glutamate dehydrogenase 1 (GLUD1) increase during differentiation of cortical neurons. Enzyme levels were
evaluated by real-time PCR. Data are normalized to the housekeeping GAPDH and relative to DIV1. (e) Western blotting analysis of glutamate decarboxylase 67 (GAD67) along the
differentiation of cortical neurons (f) Pharmacological inhibition of glutamine–glutamate pathway negatively affect cortical neuron differentiation. Cortical neurons were plated at DIV1
and untreated (CTRL) or treated with DON (10 μM) for 48 h. Representative micrographs of DIV3 cortical neurons stained with β-III-Tubulin are shown. (g) Quantification of neuronal
differentiation as in Figure 1f. (h) ATP levels in DIV6 cortical neurons treated for 24 h. Data represent mean±S.E.M. (n= 3 of independent experiments; Student’s t-test)
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respiratory capacity. However, maximal respiration rate and
spare respiratory capacity were only marginally affected by
PD98059 (Figures 6e and f). These results suggest that the
PI3K and MAPK pathways act together in the regulation of
mitochondrial biogenesis, whereas mitochondrial function is
mainly regulated by PI3K–Akt–mTOR. As glucose uptake
was affected by rapamycin treatment (Figure 6g), we have
also assessed the uptake of glucose in the same experi-
mental context. As shown in Figure 6g, PI3K inhibition
resulted in a significant reduction of glucose uptake, whereas
the inhibition of the MAPK pathway did not.
Role of reactive oxygen species (ROS) in neuronal
differentiation. Several in vitro approaches suggest that
ROS generation and signalling are involved in neuronal
differentiation.29 Thus we asked whether ROS have a role in
ex vivo differentiation of primary cortical neurons. Metabolic
analysis shows a significant increase in glutathione dis-
ulphide (GSSG) and a slight increase in GSH during
neuronal differentiation. Overall, this leads to a reduction in
GSH/GSSG ratio that fails to reach the significance
(Figures 7a–c). In addition, these changes were associated
to an increase in ROS production during neuronal differentia-
tion as shown in Figure 7d and Supplementary Figure S4b.
To explore whether this ROS production was involved in
neuronal differentiation, DIV1 cortical neurons were treated
with N-acetylcysteine (NAC),30 a ROS scavenger, and
neuronal differentiation was assessed by the expression of
Synapsin 1–2. As shown in Figure 7e, reduction of ROS
levels led to a reduction of neuronal differentiation, suggest-
ing that ROS participate in the regulation of cortical neuron
differentiation.
Next we asked whether reduced GSH synthesis affect
neuronal differentiation. Hence, we employed mice lacking of
the glutamate-cysteine ligase modifier subunit (GCLM),
a component of the glutamate cysteine ligase (GCL), the
rate-limiting enzyme of GSH synthesis (Supplementary
Figure S4a), which have reduced GSH levels in all organs.31
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As shown in Figure 7f, DIV7 cortical neurons derived from
GCLM− /− mice have higher levels of ROS and higher basal
mitochondrial respiration (Figure 7g). However, no obvious
differences were observed in mitochondrial function
(Supplementary Figures S4c and d) and in neuronal differ-
entiation assessed by the expression of Synapsin 1–2 and
GAD67 (Figure 7h) between GCLM− /− and WT cortical
neurons.
Discussion
Here we report for the first time a global metabolic profile in
cortical neurons during the physiological process of terminal
neuronal differentiation. Conversely, metabolic studies on
neurons have mainly been conducted on pathological
conditions,32–34 such as Parkinson’s35 and Alzheimer’s
disease,36–38 or during cell death.39 Therefore, unraveling
the metabolic changes underlying normal neuronal differen-
tiation is an important baseline in which to interpret those
metabolic changes associated with neurodegeneration.
Although themodel of in vitro terminal differentiation of cortical
neurons has some limitations, we have chosen it to avoid any
contribution from glia cell to the global metabolic profile of
cortical neurons.40 Thus we show that the in vitro differentia-
tion of primary cortical neurons is associated with increased
glycolysis owing, at least in part, to increased expression of
GLUT3 and of enzymes in the glycolytic pathway. Neuronal
differentiation is also associated with increased glutamine
metabolism, again at least partly owing to increased expres-
sion of enzymes such as GLS1 and GLS2, resulting in
increased expression of neurotransmitters such as glutamate
and GABA, and increased TCA cycle activity. Finally,
differentiation requires a significant increased mitochondrial
mass and function, secondary to activation of the PI3K/mTOR
axis (Figure 8). Inhibition of these pathways arrests neuronal
differentiation.
Our data suggest that the three metabolic changes we
observe during differentiation have distinct roles at different
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stages of the differentiation process. The results indicate
that glycolysis has a predominant role at an early phase
of differentiation, whereas mitochondrial bioenergetics and
glutamine are required for the later stages of differentiation,
including dendritic outgrowth and maturation.
In neurons, mitochondria are involved in the regulation
of Ca2+ homeostasis and redox signalling and in
developmental,41 synaptic plasticity14,42 as well as in cell
death.43–46 Previous reports have indicated a possible link
between mitochondria and neuronal differentiation. Indeed,
pharmacological inhibition of mitochondrial protein synthesis
by CAF resulted in a reduction of differentiation,6 and
mitochondrial morphology and movement changes with the
development of mature synapses.5 In particular, it has been
shown that PGC-1α, the master regulator of mitochondrial
biogenesis,19,47,48 regulates the formation and maintenance
of hippocampal synapses.49 Our findings not only confirm the
role of mitochondria in neuronal differentiation but also add a
further layer of complexity to mitochondrial biology in neurons.
Thus, together with an increase in mitochondrial biogenesis,
neuronal differentiation is associated with a reprogramming of
mitochondrial structure and bioenergetics. In particular,
mitochondria shift from a condensed matrix structure to the
more orthodox structure having the typical cristae-rich
morphology.50 This morphological shift is associated with
functional changes, as the early-condensed DIV1 mitochon-
dria operate near their maximal rate and have minimal spare
respiratory capacity. In contrast, in the late phase of
differentiation mitochondria have adopted a more classical
configuration and have considerable spare respiratory
capacity, indicating that mitochondria of fully differentiated
cortical neurons are proportionally less active. Moreover, our
in vitro findings are partially confirmed in vivo during postnatal
development of the cortex, where we have observed an
increase of both mtDNA and mitochondrial mass. However,
further investigations are required for assessing the contribu-
tion of mitochondrial bioenergetics in neuronal differentiation
both in embryos and in the developing brain.
Glucose is the main source of energy for the brain,51 and
although the role of glycolysis in neurons is still debated,52 our
findings indicate that, alongside its role in providing NADPH
through the PPP pathway for regenerating GSH, glucose is
crucially required for neuronal differentiation. Indeed, our
results suggest that glucose is required to support the
biosynthesis needed for neurite outgrowth and synaptic
formation. This biosynthetic role is reminiscent of the Warburg
effect observed in cancer cells and it has also been recently
postulated in the rapidly growing human child brain.53 More-
over, ATP levels are reduced after 2-DG treatment, suggesting
that glycolysis may be a major source of ATP early in the
differentiation process, especially as it is only later that
mitochondrial mass and function are increased. In agreement
with our findings, more recently it has been shown that neurons
uptake glucose and are the primary consumers of glucose.54
Glutamate is the main excitatory neurotransmitter in the
brain and although there are many pathways for glutamate
synthesis in cells, the vesicular pool in neurons is synthesized
primarily from glutamine.25 Previously, it has also been shown
that neurons under some circumstances can use glutamine
and glutamate for energy production;3 our findings would
suggest that this pathway is also involved in the regulation of
neuronal differentiation. Indeed, pharmacological inhibition of
the conversion of glutamine to glutamate leads to a reduction
of neuronal differentiation and ATP production. This finding is
also consistent with our previous observations that glutamine
withdrawal from cortical neuron in culture reduces branching
and the expression of synaptic proteins.55
Although the PI3K–Akt–mTOR pathway has emerged as a
critical regulator of neuronal activity andmorphology,27,56 here
we show that pharmacological inhibition of these pathways
resulted in a reduction of mitochondrial biogenesis and
glucose metabolism in neurons. Therefore, our findings not
only support the published role of mTOR signalling in the
regulation of dendritic arborization,11 but also suggest that
increased mitochondrial mass and function, together with
enhanced glycolysis may be required for dendrite and
synapse formation. As mTOR regulates mitochondrial biogen-
esis via TFAM,57 our data would emphasize the central critical
role of mTOR in neuronal differentiation.
Materials and Methods
Mice. Mice were bred and subjected to listed procedures under the Project
Licence PPL 40/3442 released from the UK Home Office. GCLM− /− mice were
generated as previously described.30,26
Cortical neuron preparation and treatment. Primary cortical neuronal
were prepared from E17.5 embryos mouse as previously described.23 Briefly,
cortices were harvested and cut into smaller pieces. Tissue was incubated with
1 × Trypsin (Invitrogen, Loughborough, UK) for 10 min at 37 °C. After washing with
Neurobasal medium (Invitrogen) containing 10% FCS, penicillin (100 U),
streptomycin (100 μg) (Invitrogen), and 1X Glutamax (Invitrogen), tissue was
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Figure 8 Schematic summary of the metabolic changes during terminal neuronal
differentiation. Differentiation of primary cortical neurons is associated with increased
mitochondrial biogenesis, glycolysis and glutaminolysis. Glycolysis is associated, at
least in part, with an increased expression of GLUT3 and PFKp. Increased glutamine
metabolism is partly due to an increased expression of enzymes, such as GLS1 and
GLS2. Changes in mitochondrial mass, morphology and function were correlated with
the upregulation of the master regulators of mitochondrial biogenesis, TFAM and
PGC-1α. Differentiation requires a significant increased mitochondrial mass and
function, secondary to activation of the PI3K/mTOR axis. Please see Discussion
section for further details
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resuspended by gentle pipetting. Cells were diluted to the appropriate concentration
and then plated in aforementioned medium on poly-D-lysine-coated plates. After 1 h,
medium was replaced with Neurobasal medium (Invitrogen) containing B27
supplement (Invitrogen), penicillin (100U), streptomycin (100 μg) (Invitrogen) and
1X Glutamax (Invitrogen) and maintained in culture for different days in vitro.
Cortical neurons were treated with the following drugs as indicated in figure legend.
2-DG, DON,26 CAF and NAC30 were purchased from Sigma-Aldrich (Dorset, UK).
Rapamycin, LY294002 and PD98059 were purchased from Cell Signaling
(Hitchin, UK).
Metabolic profiling. Samples were immediately stored at − 80 °C. Samples
were extracted and prepared for analysis using Metabolon’s standard solvent
extraction method. The sample preparation process was carried out using the
automated MicroLab STAR system from Hamilton Company (Reno, NV, USA).
Recovery standards were added prior to the first step in the extraction process for
QC purposes. Sample preparation was conducted using a proprietary series of
organic and aqueous extractions to remove the protein fraction while allowing
maximum recovery of small molecules. Then the resulting extract was divided into
two fractions; one for analysis by liquid chromatography (LC) and the other one for
analysis by gas chromatography. Samples were placed briefly on a TurboVap
(Zymark, Hopkinton, MA, USA) to remove the organic solvent. Each sample was
then frozen and dried under vacuum. Samples were then prepared for the
appropriate instrument, either LC/mass spectrometry (MS) or GC/MS. Instrument
variability was determined by calculating the median relative standard deviation
(RSD) for the internal standards that were added to each sample prior to injection
into the mass spectrometers. Overall process variability was determined by
calculating the median RSD for all endogenous metabolites (i.e., non-instrument
standards) present in 100% of the Client Matrix samples, which are technical
replicates of pooled samples. Following normalization to total protein determined by
Bradford assay, log transformation and imputation with minimum observed values
was performed for each compound. Welch’s two-sample t-tests were then used to
identify biochemicals that differed significantly between experimental groups. A
summary of the numbers of biochemicals that achieved statistical significance
(P≤ 0.05) as well as those approaching significance (0.05oPo0.1), is shown.
Transmission electron microscopy. For electron microscopy, cells were
fixed in 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) at 4 °C
overnight and postfixed with 1% osmium tetroxide/1% potassium ferrocyanide for
1 h at room temperature. After fixation, cells were stained en bloc with 5%
aqueous uranyl acetate overnight at room temperature, dehydrated and embedded
in Taab epoxy resin (Taab Laboratories Equipment Ltd, Aldermaston, UK). Ultrathin
sections were stained with lead citrate and recorded using a Megaview 3 digital
camera and iTEM software (Olympus Soft Imaging Solutions GmbH, Münster,
Germany) in a Jeol 100-CXII electron microscope (Jeol UK Ltd, Welwyn Garden
City, UK).
Extracellular flux (XF) analysis. Cortical neurons were seeded in XF 24-
well cell culture microplate (Seahorse Bioscience, Copenhagen, Denmark) in
quintuplicate at 3 × 105 cells/well in 1 ml growth medium and then incubated at 37 °
C in 5% CO2. Cortical neurons from GCLM− /− mice were seeded in XF 96-well
cell culture microplate (Seahorse Bioscience) in quintuplicate at 8 × 104 cells/well.
Assays were initiated by removing the growth medium from each well and replacing
it with 600–900 μl of assay medium prewarmed to 37 °C. The cells were incubated
at 37 °C for 30 min to allow media temperature and pH to reach equilibrium before
the first rate measurement. Prior to each rate measurement, the XF24 Analyser
gently mixed the assay media in each well for 10 min to allow the oxygen partial
pressure to reach equilibrium. Following mixing, OCR and ECAR were measured
simultaneously for 3–5 min to establish a baseline rate. The assay medium was
then gently mixed again for 3–5 min between each rate measurement to restore
normal oxygen tension and pH in the microenvironment surrounding the cells. After
the baseline measurement, 75–90 μl of a testing agent prepared in assay medium
was then injected into each well to reach the desired final working concentration.
This was followed by mixing for 5–10 min to expedite compound exposure to cellular
proteins, after which OCR and ECAR measurements were then made. Generally,
two to three baseline rates and two or more response rates (after compound
addition) were measured, and the average of two baseline rates or test rates was
used for data analysis. For time-resolved experiments, multiple measurements as
well as compound injections were made at the time points indicated. The values of
OCR and ECAR reflect both the metabolic activities of the cells and the number of
cells being measured. Typically, at the end of each assay cells are treated for protein
extraction.
RNA extraction and real-time PCR. Total RNA from cells was isolated
using Trizol (Invitrogen) according to the manufacturer's instructions. Total RNA
(3 μg) was reverse transcribed using RevertAid H Minus Reverse Transcriptase and
oligo(dT) (Thermo Scientific, Loughbrough, UK). qRT-PCR was performed in an ABI
PRISM 7000 Sequence Detection System (Applied Biosystem, Loughbrough, UK)
with SYBR green ready mix (Applied Biosystem) and specific primers. The
expression of each gene was defined from the threshold cycle, and the relative
expression levels were calculated by using the 2−ΔΔCt method. The following
primers were used:
HK1 Fwd 5′-GTGGACGGGACGCTCTAC-3′,
HK1 Rev 5′-TTCACTGTTTGGTGCATGATT-3′,
PKM2 Fwd 5′-GCCGCCTGGACATTGACTC-3′,
PKM2 Rev 5′-CCATGAGAGAAATTCAGCCGAG-3′,
PFKp Fwd 5′-GGAAGCCAAATGGGACTGT-3′,
PFKp Rev 5′-CGCACTACCGATGATGGTC-3′,
GLUD1 Fwd 5′-CCCAACTTCTTCTTCAAGATGGTGG-3′,
GLUD1 Rev 5′-AGAGGCTCAACACATGGTTGC-3′,
GLS1 Fwd 5′-GGGAATTCACTTTTGTCACGA-3′,
GLS1 Rev 5′-GACTTCACCCTTTGATCACC-3′,
GLS2 Fwd 5′-AGCGTATCCCTATCCACAAGTTCA-3′,
GLS2 Rev 5′-GCAGTCCAGTGGCCTTCAGAG-3′,
GLUT3 Fwd 5′-ATGGGGACAACGAAGGTGAC-3′,
GLUT3 Rev 5′-GTCTCAGGTGCATTGATGACTC-3′,
GADPH Fwd 5′-CAATGAATACGGCTACAGCAAC-3′,
GADPH Rev 5′-AGGGAGATGCTCAGTGTTGG-3′,
GPX1 Fwd 5′-CAGGAGAATGGCAAGAATGA-3′,
GPX1 Rev 5′-GAAGGTAAAGAGCGGGTGAG-3′,
SOD1 Fwd 5′-GAGCCGGCTTGGCATCCGTT-3′,
SOD1 Rev 5′-CGCGTCCTGCGGCCTTAGTC-3′,
COX2 Fwd 5′-TCTCCCCTCTCTACGCATTC-3′,
COX2 Rev 5′-CAGGTTTTAGGTCGTTTGTTG-3′,
TFB2M Fwd 5′-AAGATGGCCCTTTCGTTTATGG-3′, and
TFB2M Rev 5′-GACTGTGCTGTTTGCTTCCTG-3′.
ROS levels. Cortical neurons were trypsinized and CM-H2DCFDA (Invitrogen)
was added at the final concentration of 10 μM. Cells were incubated for 20 min at
37 °C to allow the permeabilization of the probes and were analysed by flow
cytometry acquiring 15 000 events per sample. In detail, the CM-H2DCFDA
fluorescent signal was collected in the FL1-H channel.
Glucose uptake. Glucose uptake was monitored using fluorescent 2-NBDG
(Invitrogen). Before staining cortical neurons with 2-NBDG, culture medium was
removed and the cells were incubated with fresh culture medium containing 2 mM
glucose for 15 min. Then fluorescent 2-NBDG was added at final concentration of
50 μM and cells were incubated at 37 °C with 5% CO2 for 1 h. 2-NBDG
uptake were stopped by removing the incubation medium and washing the cells
with prewarmed culture medium (2 mM glucose), harvested, centrifuged and
subsequently suspended in prewarmed culture medium (2 mM glucose). The
samples were then analysed using a FACScan flow cytometer (Becton
Dickinson, Oxford, UK).
mtDNA relative quantification. Cortical neurons were washed with
prewarmed PBS and harvested. The cell pellet were suspended with 600 μl of
extraction buffer (NaCl 75 mM, 50 mM Tris HCl pH 8.5, EDTA 5 mM, SDS 1%,
Proteinase K 500 μg/ml) and incubated for 2 h at 55 °C. Then samples were
incubated for 10 min at 95 °C to inhibit the Proteinase K and centrifuged at 8000 r.p.m.
for 15 min at 4 °C. Supernatant was recovered and the same volume of phenol/
chloroform/isoamyl alcohol (25 : 4: 1) was added. After vortexing and centrifugation
at 13 000 r.p.m. for 15 min at 4 °C, the aqueous phase was recovered and DNA was
precipitated with 1/10 NaAc (3M, pH 5.2) and 1 volume of isopropanol for 10 min at
− 20 °C. After centrifugation, the DNA pellet was washed with 70% EtOH, air dried
and dissolved in sterile water. DNA concentrations were measured using
a Nanodrop 1000 spectrometer (Thermo Scientific). The relative amount of mtDNA
was valued by qRT-PCR performed in an ABI PRISM 7000 Sequence Detection
System (Applied Biosystem) with SYBR green ready mix (Applied Biosystem) with
the following primers:
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SDHA Fwd 5′-AGACCTTGAATGAGGCTGACTGTG-3′,
SDHA Rev 5′-GAGACAAAGTCTGGCGCAACTC-3′,
ND5 Fwd 5′-TGATGGTACGGACGAACAGACG-3′, and
ND5 Rev 5′-CTGATGGTAGTCATGGGTGGAG-3′
ATP levels. Intracellular levels of ATP were measured by using the ELITEN ATP
Assay System Bioluminescence Detection Kit (Promega, Southampton, UK). Briefly,
treated and untreated cells were harvested and processed according to the
manufacturer’s instructions. The total levels of ATP were normalized to the protein
content.
Western blotting. Proteins were extracted with RIPA buffer containing an
inhibitor cocktail (Roche, Sussex, UK) and protein concentration was determined
using a Bradford dye-based assay (Bio-Rad, Hemel Hempstead, UK). Total protein
(30 μg) was subjected to SDS–PAGE followed by immunoblotting with appropriate
antibodies at the recommended dilutions. The blots were then incubated with
peroxidase-linked secondary antibodies followed by enhanced-chemiluminescent
detection using the Super Signal Chemiluminescence Kit (Thermo scientific). The
following antibodies were used: PGC-1α (rabbit, 1 : 1000, Abcam, Cambridge, UK),
MEF2 (rabbit, 1 : 500, Santa Cruz, Middlesex, UK), Phospho-S6 Ribosomal Protein
(Ser235/236) (rabbit, 1 : 100, Cell Signaling Technology, UK), S6 Ribosomal Protein
(5G10) (Rabbit, 1 : 100, Cell Signaling Technology), TFAM (rabbit, 1 : 100, Sigma,
UK), NRF1 (rabbit, 1 : 500, Life Span Bioscience, Nottingham, UK), Cleaved
caspase-3 (rabbit, 1 :1 000, Cell Signaling), GAD67 (mouse, 1 : 1000, Millipore,
Watford, UK), MitoProfile Total OXPHOS Rodent WB Antibody Cocktail (mouse,
1 : 250, Abcam, UK), LC3B (rabbit, 1 : 1000, Sigma), β-Tubulin (rabbit, 1 : 1000,
Santa Cruz), Synapsin (1 : 1000, Synaptic System, Goettingen, Germany), Actin
(1 : 5000, Sigma), Cyclophillin D (1 : 1000, Abcam), GLS2 (1 : 100, Abcam), PFKp
(1 : 500, Abcam) and GADPH (mouse, 1 : 10 000, Sigma).
Immunofluorescence. Cortical neurons were fixed with 3% paraformaldehyde
in PBS followed by treatment with 0.1% Triton X-100 for 5 min and 10% normal goat
serum in PBS for 1 h at RT. Then cells were stained at 4 °C overnight with the
following primary antibodies: neuronal-specific anti-β-III-Tubulin (1 : 2000; Promega).
After three washes (10 min, PBS), nuclei were stained with DAPI (1 : 10 000) for
10 min; this step was followed by a further wash (10 min in PBS). The coverslips were
then mounted with Aquapolymount antifading solution (Polysciences, Northampton,
UK) onto glass slides and observed under a confocal microscope (Zeiss LSM 510,
Cambridge, UK).
Statistical analysis. All results are expressed as means±S.D. Po0.05 was
considered significant. Welch’s two-sample t-tests were then used to identify
biochemicals that differed significantly between the experimental groups. Statistical
analysis were performed using GraphPad Prism 6 (La Jolla, CA, USA).
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